New heart failure drug enters first human safety tests
NCT ID NCT07547540
First seen Apr 23, 2026 · Last updated May 23, 2026 · Updated 4 times
Summary
This early-stage study tests a single dose of a new drug called LY3971297 in 90 adults with heart failure (either preserved or reduced ejection fraction). The main goal is to check for side effects and see how the body handles the drug. Participants will be in the hospital for about 4 days and have 5 follow-up visits over 2 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cerebral and Cardiovascular Center
Suita-shi, 564-8565, Japan
Contact Phone: •••-•••-••••
Contact
-
University of North Carolina, Division of Cardiology
Chapel Hill, North Carolina, 27599, United States
Contact Phone: •••-•••-••••
Contact
-
Washington University
St Louis, Missouri, 63110, United States
Contact
Conditions
Explore the condition pages connected to this study.